| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Classified under Biotechnology (Health Care sector), HYPD's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| Other | 1.35M | - | - | |
| CFO | 287.6K | - | - | |
| Dir | 170.8K | - | - | |
| Dir | 150.1K | - | - | |
| Dir | 146.9K | - | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | Jung Hyunsu | See Remarks | Buy | 8,000 | $3.70 | $29,580.00 | +0.6% | - | - | |
| Dec 31, 2025 | Knox David R. | Chief Financial Officer | Buy | 27,950 | $3.59 | $100,340.50 | +9.3% | -3.1% | - | |
| Dec 29, 2025 | Strahlman Ellen R66 | Director | Buy | 30,880 | $3.66 | $113,091.17 | +774.1% | -8.6% | - | |
| Dec 18, 2025 | Strahlman Ellen R66 | Director | Buy | 38,444 | $3.14 | $120,663.99 | +67.8% | +25.7% | - | |
| Dec 17, 2025 | Geltzeiler Michael S | Director | Buy | 30,000 | $3.01 | $90,210.00 | +51.7% | +27.9% | - | |
| Dec 17, 2025 | Walters Happy David | Director | Buy | 61,930 | $3.02 | $187,152.46 | +123.9% | +27.9% | - | |
| Aug 28, 2024 | Rowe Michael M | Chief Executive Officer | Buy | 27,071 | $0.52 | $14,076.92 | +32.6% | -78.9% | -84.0% | |
| Aug 26, 2024 | Rowe Michael M | Chief Executive Officer | Buy | 50,000 | $0.57 | $28,500.00 | +151.9% | -83.2% | -83.6% | |
| Jul 2, 2024 | Grant Stuart M. | 10% Owner | Buy | 1,515,151 | $0.66 | $999,999.66 | +16.1% | -30.5% | -73.4% | |
| Mar 28, 2024 | Grant Stuart M. | 10% Owner | Buy | 100,000 | $0.98 | $98,000.00 | +1.9% | -36.1% | -98.6% |